In this open label, randomized study we compared the influence of a dose-reduced oral
contraceptive containing 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (20 EE) with …

The use of oral contraceptives (OC) is a well established risk factor for venous thrombosis. It
has been known for many years that almost all haemostatic parameters ie plasma levels of …

Aims In October 1995 in response to the results of three studies, the Committee on the
Safety of Medicines advised doctors and pharmacists that oral contraceptives containing …

Objective To assess the risk of venous thromboembolism from use of combined oral
contraceptives according to progestogen type and oestrogen dose. Design National …

Background: A novel estradiol-based combined oral contraceptive (COC) is currently
available in many countries worldwide, including Europe and the US. Based on previous …

The effects of two progestogen-only pills containing either 75 μg desogestrel (DSG) or 30 μg
levonorgestrel (LNG) on hemostasis were investigated in a double-blind, randomized …

In Europe and North America, estrogen/progestogen oral contraception has been
associated with an increase in venous thromboembolism, myocardial infarction, and stroke …

BACKGROUND: This study investigated whether gestodene-containing oral contraceptives
(OCs) carry a higher risk of venous thromboembolism (VTE) than OCs containing progestins …

Oral contraceptives influence plasma proteins, causing changes in plasma procoagulants
and fibrinolytic effectors. Estrogen is thought to be responsible for these changes, whereas …

Cardiovascular risks have been a concern since combined oral contraceptives (OCs) were
first introduced. In the past four years new, mostly reassuring information on the safety of …